**PLEASE NOTE APPLICATIONS ARE NOW CLOSED**
The Accelerate@Babraham concept complements our ongoing support of the Cambridge life science cluster through the provision of access to the campus community and infrastructure without the need to be an established occupier on site.
Now in it's third year, the Accelerate@Babraham Start-ups Competition (StartUP@Babraham) goes one step further, giving new companies the chance to win one of five spaces on the Accelerate programme for a five-month period from September.
NEW PRIZE RECENTLY ANNOUNCED: AstraZeneca is offering the five successful StartUP@Babraham competition finalists the opportunity to pitch their businesses to an exclusive group of high-profile life sciences experts and investors at the AstraZeneca Exchange Event. The venture with the most compelling pitch will receive a £10,000 cash prize, donated by CMS Ventures, an early stage life sciences and biotech investor based in Cambridge. Due to the current Covid-19 pandemic, the date of the event is to be confirmed. More details will follow in due course!
Up to five competition finalists will win access to Accelerate@Babraham’s bio-incubator facilities, including communal equipped laboratory space, flexible workspace within our stimulating and supportive environment and access to our community hub which includes office, meeting and social spaces. In addition, finalists will receive:
APPLICATIONS ARE NOW CLOSED!
Applications for StartUP@Babraham 2020 opened on March 1st and given the current situation we have decided to extend the deadline for applications to June 30th.
Shortlisted applicants will be notified in early July and will be invited to pitch to our judging panel of business leaders via video or conference call on July 22nd. Having spoken to all shortlisted applicants the judges will choose up to five winning finalists to be accepted onto the programme.
To apply please click the button below.
The competition is open to early stage start-ups (who are yet to raise their first £1m funding/investment) with a life science sector focus, eg: therapeutics, synthetic biology, life science tools & technologies, diagnostics or any transformative healthcare solutions. Applicants must be a team of at least two members and available to move to Cambridge (UK) for the entire acceleration programme. A passion for life science, healthcare and entrepreneurship is critical!
Jane Osbourn is VP R&D at AstraZeneca (formerly MedImmune) with in depth experience of biologics drug discovery and development. She is also Chair of the BioIndustry Association (BIA), the UK trade association for innovative biotech companies.
Olivia joined SV Health Investors in August 2018 as Principal in the Biotechnology team based in London.
Dr. Vishal Gulati is a venture partner at Draper Esprit a leading European venture capital firm. His investment interests include healthtech, omics and synthetic biology.
Derek is Chief Executive of Babraham Bioscience Technologies, the company which manages and develops the Babraham Research Campus.
Maina joined Sofinnova Partners in January 2018. Maina has a long track record as a successful healthcare investor. Prior to joining, she was Director of Healthcare Investment at Touchstone Innovations (formerly Imperial Innovations) in London (UK) since 2006.
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557